PSY37 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 600/800mg Daily as Therapy for Imatinib Failing Chronic Myeloid Leukemia (CML)
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.571
https://www.valueinhealthjournal.com/article/S1098-3015(12)00636-5/fulltext
Title :
PSY37 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 600/800mg Daily as Therapy for Imatinib Failing Chronic Myeloid Leukemia (CML)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)00636-5&doi=10.1016/j.jval.2012.03.571
First page :
A105
Section Title :
Systemic Disorders/Conditions
Open access? :
No
Section Order :
36